Enlivex Therapeutics Ltd. (ENLV) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $0.81, ENLV trades at a P/E of 0.00 and an ROE of 248.08%. Market capitalisation stands at $14M.
Balance sheet quality for ENLV: current ratio of 193.2, net cash position of $5.2M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is below average: free cash flow of -$10.5M represents -1% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $0.81 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| P/E Ratio | 0.00 |
| Price / Book | 0.00 |
| EV / EBITDA | -1.20 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 248.08% |
| Return on Invested Capital | -0.49% |
| Return on Assets | 53.10% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 193.24 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ENLV | Enlivex Therapeutics Ltd. | $14M | 0.00 | 0.00 | 248.1% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -46.64% |
| 3 months | -91.31% |
| Year-to-date | -92.31% |
| 1 year | -94.85% |
| 3 years | -97.06% |
| 5 years | -99.54% |
52-Week Range
| 52-week High | $27.15 |
| 52-week Low | $0.79 |
| Avg Volume (90d) | 187K |
Related companies: CLGN · CVKD · GDTC · LSTA · MTVA · NCNA · NRSN
Explore sector: Healthcare · Biotechnology
More sections of ENLV: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks